EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma

Shuchang Zhou, Han Sun, Sun Il Choi, Jinlong Yin

Frontiers in Bioscience-Landmark · 2023

DOI: 10.31083/j.fbl2809206 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, 2023. Verfasst von Shuchang Zhou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Henan Key Laboratory of Brain Targeted Bio-Nanomedicine, School of Life Sciences & School of Pharmacy, Henan University, 475004 Kaifeng, Henan, China. Hauptthemen laut MEDLINE: Glioblastoma, Receptors, Chimeric Antigen, Brain Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adoptive chimeric antigen receptor (CAR) T cells designed to recognize specific tumor antigens have shown promising results in cancer therapy. While CAR T cell therapy has demonstrated notable clinical effectiveness for hematologic disease, efforts to develop therapies for solid tumors, including glioblastoma (GBM), have been hampered by heterogeneity, an immunosuppressive tumor microenvironment, and difficulty in trafficking. Several specific tumor antigens, such as IL13Rα2, EGFRvIII, and HER2, have been attempted in clinical trials; however, limited efficacy has been observed. In this review, we discuss the current status of CAR T therapy for GBM in clinical trials and highlight the potential target antigens for CAR T cells. Additionally, we summarize the mechanisms used to enhance their efficacy and explore the challenges and future prospects of CAR T cell therapy for GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaReceptors, Chimeric AntigenBrain NeoplasmsHumansImmunotherapy, AdoptiveReceptors, Antigen, T-CellT-LymphocytesAntigens, NeoplasmCell- and Tissue-Based TherapyTumor Microenvironment

Stichwörter der Autor:innen

CAR Tcancer therapycell therapyglioblastomaimmunotherapy

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-CellAntigens, Neoplasm

Autor:innen und Institutionen

  • Henan Key Laboratory of Brain Targeted Bio-Nanomedicine, School of Life Sciences & School of Pharmacy, Henan University, 475004 Kaifeng, Henan, China.
  • Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Henan University, 475004 Kaifeng, Henan, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhou, S., Sun, H., Choi, S. I., & Yin, J. (2023). Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2809206

Vancouver

Zhou S, Sun H, Choi SI, Yin J. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma. Frontiers in Bioscience-Landmark. 2023. doi:10.31083/j.fbl2809206

BibTeX
@article{Zhou2023,
  author = {Zhou, Shuchang and Sun, Han and Choi, Sun Il and Yin, Jinlong},
  title = {Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2023},
  doi = {10.31083/j.fbl2809206}
}
Kostenlos starten →